NYSEAMERICAN:RNN - Rexahn Pharmaceuticals Stock Price, Price Target & More

$1.55 -0.03 (-1.90 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$1.58
Today's Range$1.51 - $1.61
52-Week Range$1.42 - $4.80
Volume99,848 shs
Average Volume317,369 shs
Market Capitalization$52.33 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.35

About Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals logoRexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma. In addition, the company is involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.

Receive RNN News and Ratings via Email

Sign-up to receive the latest news and ratings for RNN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:RNN
CUSIPN/A
Phone+1-240-2685300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-26.84%
Return on Assets-15.81%

Miscellaneous

EmployeesN/A
Outstanding Shares31,740,000

How to Become a New Pot Stock Millionaire

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Frequently Asked Questions

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) issued its quarterly earnings data on Monday, March, 12th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. View Rexahn Pharmaceuticals' Earnings History.

What price target have analysts set for RNN?

5 brokers have issued 12-month target prices for Rexahn Pharmaceuticals' stock. Their predictions range from $13.00 to $20.00. On average, they expect Rexahn Pharmaceuticals' share price to reach $16.6250 in the next year. View Analyst Ratings for Rexahn Pharmaceuticals.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 2,172,608 shares, an increase of 18.0% from the March 15th total of 1,841,516 shares. Based on an average daily volume of 204,767 shares, the short-interest ratio is presently 10.6 days. Currently, 7.0% of the company's stock are short sold.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:
  • Dr. Peter D. Suzdak, Chief Exec. Officer and Director (Age 59)
  • Dr. Ely Benaim M.D., Chief Medical Officer (Age 57)
  • Dr. Lisa Elizabeth Nolan Ph.D., Chief Bus. Officer (Age 56)
  • Mr. Douglas J. Swirsky, Pres & CFO (Age 49)
  • Dr. Reza Mazhari Ph.D., VP of Translational Medicine

Has Rexahn Pharmaceuticals been receiving favorable news coverage?

News articles about RNN stock have been trending somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Rexahn Pharmaceuticals earned a news sentiment score of 0.24 on Accern's scale. They also gave headlines about the company an impact score of 46.05 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Rexahn Pharmaceuticals?

Shares of RNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of RNN stock can currently be purchased for approximately $1.55.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $52.33 million.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300.


MarketBeat Community Rating for Rexahn Pharmaceuticals (RNN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  198 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  336
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe RNN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RNN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Rexahn Pharmaceuticals in the last 12 months. Their average twelve-month price target is $16.6250, suggesting that the stock has a possible upside of 972.58%. The high price target for RNN is $20.00 and the low price target for RNN is $13.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.6250$16.6250$16.50$16.6250
Price Target Upside: 972.58% upside907.58% upside587.50% upside580.21% upside

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Consensus Price Target History

Price Target History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/12/2018HC WainwrightSet Price TargetBuy$20.00View Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$13.00View Rating Details
8/7/2017Ifs SecuritiesReiterated RatingOutperformView Rating Details
6/9/2017Rodman & RenshawReiterated RatingBuy$19.50View Rating Details
6/1/2017FBR & CoReiterated RatingOutperform$30.00 -> $14.00View Rating Details
(Data available from 4/24/2016 forward)

Earnings

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Earnings History and Estimates Chart

Earnings by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018Q4 2017($0.14)($0.09)ViewN/AView Earnings Details
11/6/2017Q3 2017($0.21)($0.15)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.15)($0.17)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.10)($0.20)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.20)($0.10)ViewN/AView Earnings Details
8/8/2016Q216($0.02)($0.01)ViewN/AView Earnings Details
5/9/2016Q116($0.02)($0.02)ViewN/AView Earnings Details
3/14/2016Q4 2015($0.30)($0.30)ViewN/AView Earnings Details
11/3/2015Q315($0.03)($0.02)ViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.02)ViewN/AView Earnings Details
5/8/2015Q1 2015($0.30)($0.20)ViewN/AView Earnings Details
4/6/2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015($0.02)($0.02)ViewN/AView Earnings Details
11/14/2014($0.03)($0.02)ViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.02)ViewN/AView Earnings Details
5/15/2014Q1 2014($0.20)($0.20)ViewN/AView Earnings Details
3/25/2014($0.06)($0.01)ViewN/AView Earnings Details
11/14/2013Q3 2013($0.20)ViewN/AView Earnings Details
8/12/2013Q2 2013($0.20)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.10)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.25)ViewN/AView Earnings Details
3/16/2012Q4 2011$0.04ViewN/AView Earnings Details
11/9/2011Q3 2011($0.16)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.61)ViewN/AView Earnings Details
5/9/2011Q1 2011($0.51)ViewN/AView Earnings Details
8/10/2009Q2 2009($0.31)ViewN/AView Earnings Details
3/16/2009Q4 2008($0.30)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Insider Trading and Institutional Ownership History

Insider Trading History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
Institutional Ownership by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2017Chang Ho AhnDirectorSell250,000$0.70$175,000.006,260,000View SEC Filing  
1/12/2015Chang Ho AhnDirectorSell314,656$0.91$286,336.96View SEC Filing  
1/12/2015Tae Heum JeongCFOSell317,272$0.91$288,717.52View SEC Filing  
6/12/2014Chang Ho AhnDirectorSell136,193$0.99$134,831.07View SEC Filing  
9/9/2013Tae Heum JeongCFOSell71,139$0.46$32,723.94View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) News Headlines

Source:
DateHeadline
Rexahn Pharmaceuticals (RNN) Given Average Recommendation of "Buy" by AnalystsRexahn Pharmaceuticals (RNN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 24 at 1:30 AM
Rexahn Pharmaceuticals (RNN) Short Interest UpdateRexahn Pharmaceuticals (RNN) Short Interest Update
www.americanbankingnews.com - April 10 at 6:56 PM
HC Wainwright Reiterates Buy Rating for Rexahn Pharmaceuticals (RNN)HC Wainwright Reiterates Buy Rating for Rexahn Pharmaceuticals (RNN)
www.americanbankingnews.com - April 1 at 7:35 PM
Rexahn Pharmaceuticals, Inc. (RNN) Receives Average Rating of "Buy" from AnalystsRexahn Pharmaceuticals, Inc. (RNN) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 30 at 1:32 AM
Rexahn Pharmaceuticals (RNN) Rating Reiterated by HC WainwrightRexahn Pharmaceuticals (RNN) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - March 27 at 12:06 AM
Rexahn Pharmaceuticals, Inc. (RNN) Short Interest UpdateRexahn Pharmaceuticals, Inc. (RNN) Short Interest Update
www.americanbankingnews.com - March 26 at 6:33 PM
Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results - GlobeNewswire (press release)Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - March 14 at 4:40 PM
Rexahn Pharmaceuticals to Present at Two Upcoming Conferences - GlobeNewswire (press release)Rexahn Pharmaceuticals to Present at Two Upcoming Conferences - GlobeNewswire (press release)
globenewswire.com - March 14 at 4:40 PM
Rexahn Pharmaceuticals to Present at Two Upcoming ConferencesRexahn Pharmaceuticals to Present at Two Upcoming Conferences
finance.yahoo.com - March 13 at 10:51 AM
Rexahn Pharmaceuticals Reports Full Year 2017 Financial ResultsRexahn Pharmaceuticals Reports Full Year 2017 Financial Results
finance.yahoo.com - March 12 at 4:44 PM
Rexahn Pharmaceuticals (RNN) Given a $20.00 Price Target by HC Wainwright AnalystsRexahn Pharmaceuticals (RNN) Given a $20.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 12 at 2:03 PM
Rexahn Pharmaceuticals, Inc. (RNN) Given Consensus Recommendation of "Buy" by BrokeragesRexahn Pharmaceuticals, Inc. (RNN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 5 at 1:30 AM
Rexahn Pharmaceuticals, Inc. (RNN) Sees Significant Growth in Short InterestRexahn Pharmaceuticals, Inc. (RNN) Sees Significant Growth in Short Interest
www.americanbankingnews.com - March 1 at 3:06 AM
Rexahn Pharmaceuticals (RNN) Scheduled to Post Earnings on MondayRexahn Pharmaceuticals (RNN) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 19 at 5:04 AM
Rexahn Pharma (RNN) Reports Data from Ongoing Phase 2a ... - StreetInsider.comRexahn Pharma (RNN) Reports Data from Ongoing Phase 2a ... - StreetInsider.com
www.streetinsider.com - February 14 at 6:37 AM
Rexahn Pharmaceuticals (RNN) Given a $20.00 Price Target at HC WainwrightRexahn Pharmaceuticals (RNN) Given a $20.00 Price Target at HC Wainwright
www.americanbankingnews.com - February 12 at 6:34 PM
Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual MeetingRexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
finance.yahoo.com - February 12 at 3:25 PM
Short Interest in Rexahn Pharmaceuticals, Inc. (RNN) Rises By 1.8%Short Interest in Rexahn Pharmaceuticals, Inc. (RNN) Rises By 1.8%
www.americanbankingnews.com - February 10 at 1:20 AM
Rexahn Pharma teams up with Zhejiang Haichang Bio to develop RX-0201 for liver cancer; shares up 1% premarket - Seeking AlphaRexahn Pharma teams up with Zhejiang Haichang Bio to develop RX-0201 for liver cancer; shares up 1% premarket - Seeking Alpha
seekingalpha.com - February 9 at 6:37 AM
Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular CarcinomaRexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma
finance.yahoo.com - February 8 at 3:24 PM
Pre-Market Technical Scan on Biotech Equities -- Revance Therapeutics, Rexahn Pharma, and Riot Blockchain - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- Revance Therapeutics, Rexahn Pharma, and Riot Blockchain - PR Newswire (press release)
www.prnewswire.com - February 8 at 6:28 AM
Rexahn Pharmaceuticals, Inc. (RNN) Given Consensus Recommendation of "Buy" by AnalystsRexahn Pharmaceuticals, Inc. (RNN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 8 at 1:32 AM
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU ... - GlobeNewswire (press release)Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU ... - GlobeNewswire (press release)
globenewswire.com - February 5 at 3:24 PM
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual MeetingRexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
finance.yahoo.com - February 5 at 3:24 PM
Rexahn Pharma (RNN) Granted Allowance for New U.S. Patent ... - StreetInsider.comRexahn Pharma (RNN) Granted Allowance for New U.S. Patent ... - StreetInsider.com
www.streetinsider.com - January 29 at 3:25 PM
Rexahn Pharmaceuticals, Inc. Secures First US Patent for Its Anticancer Drug CandidateRexahn Pharmaceuticals, Inc. Secures First US Patent for Its Anticancer Drug Candidate
finance.yahoo.com - January 29 at 3:25 PM
Rexahn Pharmaceuticals, Inc. (RNN) Sees Large Decline in Short InterestRexahn Pharmaceuticals, Inc. (RNN) Sees Large Decline in Short Interest
www.americanbankingnews.com - January 25 at 1:32 AM
Rexahn Pharmaceuticals, Inc. Forecasted to Post FY2022 Earnings of $3.02 Per Share (RNN)Rexahn Pharmaceuticals, Inc. Forecasted to Post FY2022 Earnings of $3.02 Per Share (RNN)
www.americanbankingnews.com - January 24 at 9:02 PM
Rexahn Pharma (RNN) Announces Poster Presentation of RX-3117 ... - StreetInsider.comRexahn Pharma (RNN) Announces Poster Presentation of RX-3117 ... - StreetInsider.com
www.streetinsider.com - January 22 at 3:29 PM
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual MeetingRexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
finance.yahoo.com - January 22 at 8:31 AM
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI ... - GlobeNewswire (press release)Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI ... - GlobeNewswire (press release)
globenewswire.com - January 18 at 3:39 PM
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual MeetingRexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
finance.yahoo.com - January 18 at 11:54 AM
Rexahn Pharmaceuticals, Inc. (RNN) Given Consensus Rating of "Buy" by BrokeragesRexahn Pharmaceuticals, Inc. (RNN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 14 at 1:32 AM
Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018 - GlobeNewswire (press release)Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018 - GlobeNewswire (press release)
globenewswire.com - January 8 at 3:28 PM
Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018
finance.yahoo.com - January 8 at 11:09 AM
Rexahn Pharma (RNN) Names Douglas J. Swirsky as President and CFO - StreetInsider.comRexahn Pharma (RNN) Names Douglas J. Swirsky as President and CFO - StreetInsider.com
www.streetinsider.com - January 6 at 8:07 AM
Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer - GlobeNewswire (press release)Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer - GlobeNewswire (press release)
globenewswire.com - January 5 at 8:02 AM
Rexahn Pharmaceuticals (RNN) Downgraded by Zacks Investment Research to "Hold"Rexahn Pharmaceuticals (RNN) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 4 at 3:38 PM
Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial OfficerRexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer
finance.yahoo.com - January 4 at 10:43 AM
The 7 Notable Biotechs With Data Expected By Years End - BenzingaThe 7 Notable Biotechs With Data Expected By Year's End - Benzinga
www.benzinga.com - December 31 at 8:10 AM
Short Interest in Rexahn Pharmaceuticals, Inc. (RNN) Drops By 6.6%Short Interest in Rexahn Pharmaceuticals, Inc. (RNN) Drops By 6.6%
www.americanbankingnews.com - December 28 at 2:09 AM
Rexahn Pharmaceuticals, Inc. (RNN) Receives Consensus Rating of "Buy" from AnalystsRexahn Pharmaceuticals, Inc. (RNN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - December 20 at 1:28 AM
Rexahn Pharmaceuticals, Inc. (RNN) Sees Significant Decrease in Short InterestRexahn Pharmaceuticals, Inc. (RNN) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - December 12 at 1:50 AM
Rexahn Pharmaceuticals, Inc. (RNN) to Post FY2017 Earnings of ($0.91) Per Share, Seaport Global Securities ForecastsRexahn Pharmaceuticals, Inc. (RNN) to Post FY2017 Earnings of ($0.91) Per Share, Seaport Global Securities Forecasts
www.americanbankingnews.com - November 30 at 6:30 AM
Rexahn Pharmaceuticals, Inc. (RNN) Sees Significant Increase in Short InterestRexahn Pharmaceuticals, Inc. (RNN) Sees Significant Increase in Short Interest
www.americanbankingnews.com - November 27 at 8:24 PM

SEC Filings

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.